Antibiotic Resistance Market Report 2025

The antibiotic resistance market size has grown strongly in recent years. It will grow from $12.21 billion in 2024 to $12.89 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to lack of new antibiotics, misuse and overuse of antimicrobials in humans, animals, and plants, highly contaminated waste effluents, low vaccination rates, lack of diagnostic tools.

The antibiotic resistance market size is expected to see strong growth in the next few years. It will grow to $16.97 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to incomplete treatment courses, globalization and travel, poor infection prevention and control, self-medication, cross-species transmission, high population density. Major trends in the forecast period include technological innovations in drug delivery, global collaboration for surveillance, expanding role of artificial intelligence, surge in novel therapies.

The increasing prevalence of drug-resistant infections is expected to drive the growth of the antibiotic-resistance market in the future. Drug-resistant infections are caused by bacteria that have developed resistance, making the infections significantly harder or even impossible to treat. Antimicrobial resistance drugs aid in treating various drug-resistant infections by improving antibiotic treatment outcomes for both target and non-target pathogens, depending on the specifics of resistance mechanisms and microbiome community interactions. For example, in November 2023, a report from the UK Health Security Agency, a government body, estimated that around 58,224 individuals in England had an antibiotic-resistant infection in 2022, reflecting a 4% rise from the 55,792 cases recorded in 2021. Thus, the increasing prevalence of drug-resistant infections is driving the growth of the antibiotic-resistance market.

The escalation in healthcare expenditure is poised to fuel the growth trajectory of the antibiotic resistance market. Healthcare expenditure denotes the cumulative financial resources invested in healthcare-related goods and services within a specified timeframe. Increased healthcare spending plays a pivotal role in propelling the antibiotic resistance market by fostering heightened research, development, and adoption of innovative treatments to counter the challenges posed by antibiotic-resistant infections. Notably, as per the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services in March 2022, projections indicate an estimated annual growth rate of 5.1% in national health spending between 2021 and 2030, reaching nearly $6.8 trillion. Moreover, the anticipated annual growth rates of 7.2% for Medicare spending and 5.6% for Medicaid spending from 2021 to 2030 underscore the substantial contribution of growing healthcare expenditure to the expansion of the antibiotic resistance market.

The antibiotic resistance market is witnessing a prominent trend centered on product innovations. Key players within this market are dedicated to pioneering innovative products to solidify their market presence. For instance, in January 2023, Alkem Laboratories Limited, an India-based pharmaceutical firm, introduced Zidavi. This novel antibiotic, a combination of ceftazidime and avibactam, addresses multi-drug resistant (MDR) infections, ensuring accessibility, affordability, and availability for critically ill patients. Zidavi, available in sterile powdered concentrate for reconstitution, offers a distinctive solution for treating infections caused by MDR gram-negative pathogens. Its formulation in single-dose vials provides an effective alternative for treating hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) linked to meropenem and colistin resistance.

Major enterprises in the antibiotic resistance market are strategically fostering partnerships to innovate and create the next generation of antimicrobial agents alongside practical diagnostics in the fight against Antimicrobial Resistance (AMR). These strategic collaborations involve leveraging complementary strengths and resources to achieve mutual success. For example, in July 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, and Evotec SE, a German biotechnology firm, joined forces with bioMérieux, a France-based diagnostic solutions provider. This partnership resulted in the formation of Aurobac Therapeutics SAS, aiming to pioneer a novel precision medicine strategy spanning diagnosis to treatment by harnessing the collective expertise of the founding companies. Their collaborative efforts aim to develop innovative antimicrobials coupled with effective diagnostics to counter the challenge posed by Antimicrobial Resistance (AMR).

In July 2022, Innoviva Inc., a pharmaceutical company based in the United States, successfully acquired Entasis Therapeutics Holdings Inc for an undisclosed sum. This strategic acquisition is designed to enhance Innoviva Inc's product portfolio focused on addressing multidrug-resistant gram-negative bacteria, providing a competitive edge in the market. Entasis Therapeutics Holdings Inc., a US-based company, specializes in the development of innovative antibacterial solutions for the treatment of severe bacterial infections resistant to conventional drugs.

Major companies operating in the antibiotic resistance market include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., Thermo Fisher Scientific Inc, AstraZeneca, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Bio-Rad Laboratories Inc, Eppendorf Corporation, Takara Bio Inc, Wockhardt Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics Plc, Seres Therapeutics Inc, Armata Pharmaceuticals Inc.

North America was the largest region in the antibiotic resistance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibiotic resistance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antimicrobial resistance refers to the phenomenon where microorganisms, including bacteria and fungi, develop the ability to withstand the effects of medications designed to eliminate them. This resistance poses a significant challenge in the treatment of infections and, in severe cases, can lead to fatalities.

The primary classes of drugs associated with antibiotic resistance include beta-lactam antibiotics, cephalosporins, quinolone antibiotics, macrolide antibiotics, tetracyclines, oxazolidinones, and others. Beta-lactam antibiotics, characterized by a beta-lactam ring in their chemical structure, work by preventing the construction of bacterial cell walls. They achieve this by covalently binding to crucial penicillin-binding proteins (PBPs), inhibiting the growth of organisms. Pathogens affected by these drugs include Staphylococcus aureus, Staphylococcus pneumonia, Neisseria gonorrhoeae, Enterococcus faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile, among others. These drugs are employed in the treatment of various diseases such as urinary tract infections, intra-abdominal infections, bloodstream infections, and Clostridium difficile infections. The mechanisms of action encompass protein synthesis inhibitors, cell wall synthesis inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, and others. These drugs are utilized by diverse end-users, including hospitals, homecare, specialty clinics, and more.

The antibiotic resistance market research report is one of a series of new reports that provides antibiotic resistance market statistics, including the antibiotic resistance industry global market size, regional shares, competitors with an antibiotic resistance market share, detailed antibiotic resistance market segments, market trends, and opportunities, and any further data you may need to thrive in the antibiotic resistance industry. This antibiotic resistance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antibiotic resistance market consists of sales of antibiotic drug classes such as carbapenems, glycopeptide antibiotics, penicillin, fluoroquinolones, trimethoprim-sulfamethoxazole, lincosamides, aminoglycosides, polymyxins, and nitroimidazoles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.